Home / Community / News / News

News

09/26/2017 - 3:29pm

AMO Pharma released interim results for a Phase 2a safety and toxicity study of Tideglusib (also known as AMO-02) for adolescents and adults with congenital myotonic dystrophy.

09/18/2017 - 11:00am

New data is available on the frequency, progression and treatment of GI symptoms in DM1 and DM2.

09/18/2017 - 10:49am

A new review article assesses the current status of and recommends future directions for brain imaging studies in DM1.

09/18/2017 - 10:41am

Given the brain manifestations of DM1, how aware are most patients of the impact and progression of their disease?

08/15/2017 - 10:49am

Learn more about Dr. Ami Mankodi, principal investigator at the National Institutes of Health’s (NIH) National Institute of Neurological Disorders and Stroke (NINDS) in Bethesda, Maryland. Dr. Mankodi has been involved in research that has helped shape a fundamental biologic and molecular understanding of myotonic dystrophy (DM).

Partners

University of Florida Logo 100px.png Houston Methodist Logo 100px.png University of Iowa 100px.png University of Kansas Logo 100px.png National Institute of Health 100px.png Ohio State University Logo 100px.png University of Rochester 100px.png Stanford University Logo 100px.png University of Utah Logo 100px.png Virginia Commonwealth University Logo 100px.png Wyck Logo 150px.png

© Myotonic Dystrophy Foundation. All rights reserved.